Arch Therapeutics, Inc. (OTCBB: ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking during surgery and trauma care. The company’s products are based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch’s flagship development stage product candidate, AC5™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. For more information, visit the company’s website at www.archtherapeutics.com